(Q51558539)

7 April 2018

title

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. (English)

1 reference

7 April 2018

1 reference

Gregorio F

1

1 reference

7 April 2018

Ambrosi F

2

1 reference

7 April 2018

Manfrini S

3

1 reference

7 April 2018

Velussi M

4

1 reference

7 April 2018

Carle F

5

1 reference

7 April 2018

Testa R

6

1 reference

7 April 2018

Merante D

7

1 reference

7 April 2018

Filipponi P

8

1 reference

7 April 2018

publication date

1 December 1999

1 reference

7 April 2018

published in

Diabetic Medicine

1 reference

7 April 2018

volume

16

1 reference

7 April 2018

issue

12

1 reference

7 April 2018

page(s)

1016-1024

1 reference

7 April 2018

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Comparison of tolbutamide and metformin in elderly diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

The fibrinolytic system in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00201.X

10.1046/J.1464-5491.1999.00201.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

10656230

1 reference

7 April 2018